GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial ...

Both Indiana University and Memorial Sloan Kettering Cancer Center (MSKCC) have published their series’ of salvage high-dose chemotherapy, Indiana using the carboplatin + etoposide regimen and MSKCC ...

One patient with TNBC describes the challenges she faced trying to de-escalate a grueling treatment regimen despite warnings ...

The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term ...

Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall ...

Combination treatment with ibrilatazar and chemotherapy has demonstrated “promising efficacy and safety” in patients with advanced squamous non-small cell lung cancer (NSCLC), according to researchers ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Preoperative chemoradiotherapy was administered as described in CROSS. Carboplatin at a dose based on an area under the concentration–time curve of 2 mg per milliliter per minute and paclitaxel ...

For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with FLOT leads to improved survival compared with preoperative chemoradiotherapy.